Press Releases - Regeneron Pharmaceuticals Inc.
WEBRegeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
Regeneron Announces Formation of Regeneron Cell Medicines ...
WEBTARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its ...
Regeneron Announces Encouraging Topline Phase 2 Data of High ...
WEBAug 24, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® …
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene ...
WEBAug 9, 2023 · Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss. Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial
Regeneron Announces Formation of Regeneron Cell Medicines ...
WEBTARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy...
Regeneron Pharmaceuticals: Delivering Life-transforming Medicines
WEBRegeneron News: Sep 27th. Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Regeneron Strengthens Commitment to Oncology through …
WEBTARRYTOWN, N.Y., June 2, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its intent to purchase Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo ® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine. The ...
News Release - Regeneron Pharmaceuticals Inc.
WEBMay 4, 2022 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2022 and provided a business update.
Regeneron Pharmaceuticals, Inc. (REGN) Latest Stock News ...
WEBGet the latest Regeneron Pharmaceuticals, Inc. (REGN) stock news and headlines to help you in your trading and investing decisions.
Regeneron's COVID antibody drug shows protection for up to 8 ...
WEBNov 8 (Reuters) - Regeneron Pharmaceuticals Inc (REGN.O) said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two...
- Some results have been removed